Please sign in to follow a disease.
New epilepsy drug tested as standalone treatment
NCT ID NCT06453213
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether cenobamate, already approved for epilepsy, works well when used alone in adults with partial-onset seizures. About 49 participants will take either 100 mg or 200 mg daily, and researchers will track how many become seizure-free for 26 weeks. The goal is to gather more data on its effectiveness as a monotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cenobamate
What this could lead to
If successful, this could confirm cenobamate as a reliable monotherapy option for adults with partial-onset seizures, offering better seizure control.
What could go wrong
This is a small, open-label Phase 4 study with no placebo group, so results may be less definitive. Some people may still have seizures or side effects like dizziness or drowsiness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL ONSET SEIZURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Neuroscience Research
Phoenix, Arizona, 85032, United States
-
Bluegrass Epilepsy Research LLC
Lexington, Kentucky, 40504, United States
-
Center For Neurosciences
Tucson, Arizona, 85718, United States
-
Clinical Trials Inc
Little Rock, Arkansas, 72205, United States
-
Consultants In Epilepsy and Neurology
Boise, Idaho, 83702, United States
-
DHR Health Institute for Research and Development
Edinburg, Texas, 78539, United States
-
Elite Clinical Research
Miami, Florida, 33144, United States
-
Hartford Hospital
Hartford, Connecticut, 06102, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hoag Physician Partners
Newport Beach, California, 92663, United States
-
John Hopkins Epilepsy Center
Baltimore, Maryland, 21287, United States
-
Knight Neurology
Rockledge, Florida, 32955, United States
-
Louisiana State University Health Sciences
Shreveport, Louisiana, 71103, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
NY Neurology Associates
New York, New York, 10003, United States
-
Neuro Pain Medical Center
Fresno, California, 93710, United States
-
University of Missouri Health Care
Columbia, Missouri, 65212, United States
-
Wayne Neurology PLC
Plymouth, Michigan, 48170, United States
-
Yale School of Medicine - Yale-New Haven Hospital
New Haven, Connecticut, 06519, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.